Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27705687 | 1.00 | HDAC8 (0.58) | HDAC8KLK5ACEDPP8DPP9 | |
| SCHEMBL27705637 | 1.00 | HDAC8 (0.58) | HDAC8KLK5ACEDPP8DPP9 | |
| SCHEMBL27726211 | 0.92 | HDAC8 (0.57) | HDAC8ACEDPP8DPP9KMT2A | |
| SCHEMBL27726210 | 0.92 | HDAC8 (0.57) | HDAC8ACEDPP8DPP9KMT2A | |
| SCHEMBL22962224 | 0.92 | HDAC8 (0.57) | HDAC8ACEDPP8DPP9KMT2A | |
| SCHEMBL27705646 | 0.87 | HDAC8 (0.55) | HDAC8ACECXCR3MAPK1 | |
| SCHEMBL22962366 | 0.87 | DPP8 (0.53) | HDAC8ACEDPP8DPP9KMT2A | |
| SCHEMBL27726227 | 0.87 | HDAC8 (0.56) | HDAC8ACEDPP8DPP9CTSS | |
| SCHEMBL27726221 | 0.87 | HDAC8 (0.56) | HDAC8ACEDPP8DPP9CTSS | |
| SCHEMBL27726233 | 0.86 | HDAC8 (0.45) | HDAC8KLK5ACECXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040150-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2021-02-11 | — | — | US | disclosed |
| WO-2021026492-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | Humanwell Pharmaceutical US (US) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040150-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | OPRK1, OPRL1, OPRD1 | HDAC8 3697/4885KLK5 964/4885ACE 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.